ETSP Current Models and Workflow

Drug Resistant Epilepsy Workflow

Identification Phase

1. Acute Seizure Models
   1. 6 Hz Electrical Stimulation Test (mouse, rat)
   2. Maximal Electroshock Seizure (MES) Test (mouse, rat)
2. Behavioral Tolerability Screens
   1. Rotarod Test (mouse)
   2. Minimal Motor Impairment (rat)
   3. Locomotor Activity (rat)
   4. Modified Irwin Test (rat)
3. Chronic Seizure Models
   1. Corneal Kindling Seizure Test (mouse)
   2. Spontaneous Bursting Slice from Post-Kainic Status Epilepticus (rat, in vitro)

Differentiation Phase

4. Acute Dosing
   1. Intra-Hippocampal Kainate Model (mouse)
   2. Lamotrigine-Resistant Amygdala Kindling Model (rat)
5. Subchronic Dosing
   1. Intra-Amygdala Kainate Model (mouse)
   2. Post-Kainic Acid Status Epilepticus-Induced Spontaneous Recurrent Seizures Model (rat) – Phase I
   3. Post-Kainic Acid Status Epilepticus-Induced Spontaneous Recurrent Seizures Model (rat) – Phase II
6. Ancillary Drug Resistant Epilepsy Models
   1. Benzodiazepine Resistant Lithium-Pilocarpine Status Epilepticus Model (rat)
   2. Theiler’s Murine Encephalomyelitis Virus Model (mouse)
   3. Dravet Syndrome Model (mouse)

Miscellaneous Tests and Procedures

1. 1. Pentylenetetrazol Seizure Threshold Test (mouse, rat)
   2. Time to Peak Effect (TPE), Effective dose (ED50), Toxic Dose (TD50)
   3. Experimental Animals and Animal Care

Disease Prevention and Modification

1. 1. What is Disease Prevention and Modification?
   2. Post-Kainic Acid Status Epilepticus-Induced Spontaneous Recurrent Seizures Model (rat)
   3. Intra-Hippocampal Kainate Model (mouse)